Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat maintenance after autologous stem cell transplant in multiple myeloma with less than complete remission
ACTRN12613000219785Phase 2Completed
- Sponsor
- The Alfred Hospital
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in multiple myeloma (MM), sponsored by The Alfred Hospital. Primary endpoint: Rate of conversion to complete remission or very good partial response. Started Sep 2012; status: completed.
02
Drugs
panobinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12613000219785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000219785.